Phase 2Not yet recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
- Sponsor
- NS Pharma, Inc. (Industry)
- Enrolment
- 135 planned
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- NS-863 Low Dose; NS-863 High Dose; NS-863 Placebo
- Ages
- adults, older adults
- Registry
- NCT07441200, CTIS2025-525114-38-00
Full record on ClinicalTrials.gov
From the registry
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
Primary outcomes
- Change in pulmonary vascular resistance (PVR) at week 24
- Number of participants who experienced an adverse event (AE) up to approximately 24 weeks.
History
Study completion expected
Primary completion expected
Started
Registered